← Back

Wire · operational-macro

Oral Infilbray Wins Early FDA Approval as First Treatment for Brain-Related Symptoms of ...

Published

19 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at medicaldaily.com →

◆ Verified

Fusion42 · 19 November 2026 · Fusion42 review

The FDA approved Infilbray (venglustat), the first oral treatment targeting neurological symptoms of type 3 Gaucher disease, allowing it to cross the blood-brain barrier and improve brain-related symptoms. The approval is based on a phase 3 trial showing neurological improvement over standard enzyme replacement therapy and includes serious psychiatric warnings.

This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 18 Nov 2026 and 20 Nov 2026.

◆ ◆ The Wire takeaway

You face a new option in rare neurological diseases as FDA clearing Infilbray opens brain-targeting treatment for type 3 Gaucher disease. This puts a spotlight on developing oral drugs that cross the blood-brain barrier and could expand your market beyond enzyme infusions.

◆ Coverage

7 sources · first reported 18 Nov 2026 · latest 20 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalrare-diseaseneurological-treatmentorphan-druggenzymesanofi